14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
BHST vs JBSS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, John B. Sanfilippo & SON (JBSS) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BHST carries a Unified Composite Score of 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin), whereas JBSS carries 47.3/100 (HOLD) at $61.07 (10.1x Forward P/E, 6.7% operating margin).
Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. JBSS 47.3/100 HOLD), JBSS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.7% vs. -18.0% operating margin) and revenue trajectory (-3.5% vs. +3.8% YoY).
Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile JBSS is in a Breakdown options structure phase (RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Packaged Foods value chain with $710.6M market capitalization and 6.7% operating margin.
OpEx & R&D Reinvestment11.0% of Rev ($128M)
90D Engineering Disclosures0 Published
Investor FAQ BHST vs JBSS Key Questions & Quantitative Answers
As of Nov 20, 2026, John B. Sanfilippo & SON (JBSS) is the stronger overall head-to-head candidate over BioHarvest Sciences Inc. (BHST) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BHST carries a Unified Composite Score of 58.2/100 (HOLD) at $1.30 (N/M Forward P/E, -18.0% operating margin), whereas JBSS carries 47.3/100 (HOLD) at $61.07 (10.1x Forward P/E, 6.7% operating margin). Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. JBSS 47.3/100 HOLD), JBSS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.7% vs. -18.0% operating margin) and revenue trajectory (-3.5% vs. +3.8% YoY). Technical & Structure Timing Caution: BHST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2); meanwhile JBSS is in a Breakdown options structure phase (RSI 50.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BHST leads the Growth & Scale pillar: BHST posts +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin), compared with JBSS at -3.5% YoY revenue growth and -30.2% YoY earnings growth on $1.17B TTM revenue (17.7% gross margin, 6.7% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BHST cumulative revenue shifted +200.0% while JBSS shifted +34.1%. In operating R&D and SG&A reinvestment, BHST deploys 77.0% of Rev ($27M) (0 90-day corporate R&D disclosures) versus 11.0% of Rev ($128M) (0 disclosures) for JBSS.
JBSS screens cheaper on headline valuation multiples. BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin), whereas JBSS trades at 10.1x Forward P/E, 12.7x Trailing P/E, 1.52x PEG, and 0.7x EV/Revenue (2.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHST (-142.5% ROE) versus JBSS (15.4% ROE) capital efficiency.
In options market volatility and institutional positioning, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk). By comparison, JBSS carries 92.9% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.21β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.